For decades, multiple sclerosis (MS) research has focused largely on the inflammatory lesions visible on MRI scans. Yet new ...

The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s ...

But, in the Gemini trials, tolebrutinib failed on the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when ...

Providing evidence for a new online MS assessment tool, researchers discovered the overlooked subtype in patients of all ages ...

Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosisParis, September 22, 2025. The US ...

Sanofi's tolebrutinib review for non-relapsing multiple sclerosis has been extended by the FDA until December 2025.

Barcelona, Spain and Düsseldorf, Germany – 22 September, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system ...

After her own multiple sclerosis diagnosis 10 years ago, Parisa Khosravi became an advocate and a clinician for an autoimmune ...

A great deal of research has been conducted, and particularly of the macular unmyelinated axons of the retinal ganglion cells ...

In this article, ACRO explores multiple sclerosis—a silent battle unfolding within the central nervous system.

Columnist Desiree Lama struggles to effectively manage stress, but given her multiple sclerosis, learning to do so is vital, ...

Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis Barcelona, Spain and Düsseldorf, ...